Chiron FGF-2 CAD Therapy Phase II Trial Shows Efficacy In Older Patients
This article was originally published in The Gray Sheet
Executive Summary
Phase II data from Chiron's FGF-2 initializing revascularization support trial (FIRST) for the recombinant fibroblast growth factor-2 protein therapy in no-option coronary artery disease (CAD) patients show achievement of the primary efficacy endpoint of increased exercise capacity at 90 days in older patients, investigators report.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.